The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory Healthcare Network
Atlanta, Georgia, United States
- the Johns Hopkins Hospital
Baltimore, Maryland, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Mount Sinai Beth Israel
New York, New York, United States
- Baylor University Medical Center Dallas
Dallas, Texas, United States
- Baylor College of Medicine
Houston, Texas, United States
- University of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Nov 2020
- Primary completion
- 1 Feb 2024
- Completion
- 2 Mar 2024
- Last update posted
- 30 Apr 2026
- Registered enrollment
- 103
- Registry id
- NCT04619680
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.